📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. (2018)

First Author: Liu Y

Attributed to: Novel strategies to detect and eliminate persistent Mycobacterium tuberculosis - applications in a murine Cornell model funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkx467

PubMed Identifier: 29244108

Publication URI: http://europepmc.org/abstract/MED/29244108

Type: Journal Article/Review

Volume: 73

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 3

ISSN: 0305-7453